Alpine is a clinical-stage specialty pharmaceutical company focused on discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune/inflammatory diseases. Our proprietary Variant Immunoglobulin Domain™ (“vIgD™”) scientific platform uses a process known as directed evolution to create therapeutics potentially capable of modulating human immune system proteins. Our vIgD platform creates molecules which can be formatted in many different ways, including standard Fc fusion proteins, localized Fc fusion proteins, and monoclonal antibody fusion proteins as well as formulated as a Transmembrane Immunomodulatory Protein (“TIP™”) or as a Secreted Immunomodulatory Protein (“SIP™”). We completed enrollment in the first human clinical trial of ALPN-101, our first-in-class dual CD28/ICOS antagonist in October 2019. ‘BALANCE’, a Phase 1b/2 clinical trial in acute GVHD is expected to begin enrollment in 2020. ALPN-202, our conditional CD28 costimulator and dual checkpoint inhibitor, is expected to begin Phase 1 trials in cancer patients in 2020.